Zusammenfassung
Hintergrund: Das lokal fortgeschrittene (T3 - 4) nicht-kleinzellige Bronchialkarzinom mit pulmonalen Lymphknotenmetastasen (N1) beinhaltet unterschiedliche Tumormanifestationen, die verschiedenen lymphatischen Metastasierungsmustern und möglicherweise Prognosen entsprechen. Patienten und Methode: Retrospektiv wurden die Krankenblätter und Verlaufsunterlagen der 181 Patienten mit pathologischem Tumorstadium IIIA-pT3N1 und IIIB-pT4N1 erfasst, die im Zeitraum 1990 - 1995 operiert wurden. Der Altersmedian betrug 62 Jahre (Bereich: 34 - 80 Jahre). Ergebnisse: Nach 188 resektiven Eingriffen betrug die 30-Tage-Letalität 3,7 %. Die folgende Analyse betrifft die 181 überlebenden Patienten, wobei 110 (60,8 %) Pneumonektomien und 71 (39,2 %) Lobektomien/Bilobektomien durchgeführt wurden. Das pathologische Stadium nach der UICC-Klassifikation 1997 lautete T3N1 in 128 (70,7 %) und T4N1 in 53 (29,3 %). Ein metastatischer Befall der hilären, interlobären und lobären Lymphknoten wurde in 44 (24,3 %), 17 (9,4 %) bzw. 27 (14,9 %) Patienten nachgewiesen, eine direkte Lymphknoteninfiltration in 93 Patienten (51,4 %). Die 3-, 5- und 10-Jahres-Überlebensraten nach Kaplan-Meier betrugen für N1 hilär 23 %, 13 % und 8 %, für N1 interlobär 18 %, 6 % und 0 %, für N1 lobär 48 %, 37 % und 22 %, und für N1 direkt 32 %, 27 % und 21 %. Der Befall der hilären Lymphknoten korrelierte mit einer eindeutig ungünstigeren Prognose (p = .0366). Schlussfolgerungen: Die metastatische Absiedlung in hiläre Lymphknoten bei lokal fortgeschrittenem NSCLC kann prognostisch als initiale N2-Erkrankung betrachtet werden und erfordert eine entsprechende Behandlung. Die direkte Infiltration der pulmonalen Lymphknoten erscheint prognostisch weniger ungünstig für die betroffenen Patienten.
Abstract
Background. The locally advanced (T3 - 4) non-small cell lung cancer with pulmonary lymph node metastases (N1) is a mixture of different subgroups of disease with varying pattern of tumor extension and long-term survival rates. Patients and methods: We retrospectively reviewed hospital records and follow-up data of 181 patients operated on between 1990 and 1995 with pathological stage IIIA-pT3N1 and IIIB-pT4N1. Median age was 62 years (range 34 - 80). Results: The operative mortality was 3.7 %. The analysis was carried out on the 181 hospital survivors. The operative procedure was a pneumonectomy in 110 cases (60.8 %) and a lobectomy/bilobectomy in 71 (39.26 %). The pathological stage according to the UICC TNM-Classification of 1997 was T3N1 in 128 (70.7 %) and T4N1 in 53 (29.3 %). We observed a metastatic involvement of the hilar, interlobar and lobar lymph nodes in 44 (24.3 %), 17 (9.4 %), and 27 (14.9 %) patients, respectively, whereas a direct infiltration in 93 patients (51.4 %). The actuarial overall 3-, 5- and 10-year survival rates for N1 hilar was 23 %, 13 % and 8 %, for N1 interlobar was 18 %, 6 % and 0 %, for N1 lobar was 48 %, 37 % and 22 %, and for N1 direct was 32 %, 27 % and 21 %, respectively. The involvement of hilar lymph nodes correlates with a worse prognosis (p = .0366). Conclusions: Metastases to the hilar lymph nodes in locally advanced NSCLC can be considered an initial N2-disease and should be treated correspondingly. Lymph node involvement by direct invasion is associated with a relatively more favourable prognosis for the patients.
Literatur
1
PORT Meta-analysis Trialists Group .
Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials.
Lancet.
1998;
352
257-263
2
Mountain C F.
Revisions in the International System for staging lung cancer.
Chest.
1997;
111
1710-1717
3
Fujimoto T, Zaboura G, Fechner S. et al .
Completion pneumonectomy: Current indications, complications, and results.
J Thorac Cardiovasc Surg.
2001;
121
484-490
4 World Health Organization .International histological classification of tumours. Geneva: World Health Organization 1969 - 1981; 2nd ed. Berlin: Springer-Verlag 1988-Present
5
Mountain C F, Dresler C M.
Regional lymph node classification for lung cancer staging.
Chest.
1997;
111
1718-1723
6
Kaplan E L, Meier P.
Nonparametric estimation from incomplete observations.
J Am Stat Assoc.
1958;
53
457-481
7
Mantel N.
Evaluation of survival data and two new rank order statistics arising in its consideration.
Cancer Chemother Rep.
1966;
50
163-170
8
Cox D R.
Regression models and life tables.
J R Stat Soc B.
1972;
34
187-220
9
Yano T, Yokoyama H, Inoue T. et al .
Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level: lobar or hilar nodes.
J Thorac Cardiovasc Surg.
1994;
107
1398-1402
10
van Velzen E, Snijder R J, Brutel de la Riviere A. et al .
Type of lymph node involvement influences survival rates in T1N1M0 non-small cell lung carcinoma. Lymph node involvement by direct extension compared with lobar and hilar node metastases.
Chest.
1996;
110
1469-1473
11
van Velzen E, Snijder R J, Brutel de la Riviere A. et al .
Lymph node type as a prognostic factor for survival in T2 N1 M0 non-small cell lung carcinoma.
Ann Thorac Surg.
1997;
63
1436-1440
12
van Velzen E, Brutel de la Riviere A, Elbers H J. et al .
Type of lymph node involvement and survival in pathologic N1 stage III non-small cell lung carcinoma.
Ann Thorac Surg.
1999;
67
903-907
13
Asamura H, Suzuki K, Kondo H. et al .
Where is the boundary between N1 and N2 stations in lung cancer?.
Ann Thorac Surg.
2000;
70
1839-1845
discussion.
1845-1846
14
Maggi G, Casadio C, Mancuso M. et al .
Resection and radical lymphadenectomy for lung cancer: prognostic significance of lymphatic metastases.
Int Surg.
1990;
75
17-21
15
Martini N, Burt M E, Bains M S. et al .
Survival after resection of stage II non-small cell lung cancer.
Ann Thorac Surg.
1992;
54
460-465
discussion.
466
16
Riquet M, Manac'h D, Le Pimpec-Barthes F. et al .
Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung.
Ann Thorac Surg.
1999;
67
1572-1576
17
Yoshino I, Nakanishi R, Osaki T. et al .
Unfavorable prognosis of patients with stage II non-small cell lung cancer associated with macroscopic nodal metastases.
Chest.
1999;
116
144-149
18
Naruke T, Goya T, Tsuchiya R. et al .
Prognosis and survival in resected lung carcinoma based on the new international staging system.
J Thorac Cardiovasc Surg.
1988;
96
440-447
19 Marra A, Hillejan L, Zaboura G. et al .Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis. J Thorac Cardiovasc Surg 2002 [in press]
20
Ferguson M K, Little A G, Golomb H M. et al .
The role of adjuvant therapy after resection of T1 N1 M0 and T2 N1 M0 non-small cell lung cancer.
J Thorac Cardiovasc Surg.
1986;
91
344-349
21
Marks L B, Prosnitz L R.
Postoperative radiotherapy for lung cancer: the breast cancer story all over again?.
Int J Radiat Oncol Biol Phys.
2000;
48
625-627
22
Sawyer T E, Bonner J A, Gould P M. et al .
Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma.
Ann Thorac Surg.
1999;
68
1171-1176
23
Wagner H.
Postoperative adjuvant therapy for patients with resected non-small cell lung cancer: still controversial after all these years.
Chest.
2000;
117
110S-118S
24
Bunn P A, Mault J, Kelly K.
Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer. A time for reassessment?.
Chest.
2000;
117
119S-122S
25
Strauss G M.
Role of chemotherapy in stages I to III non-small cell lung cancer.
Chest.
1999;
116
509S-516S
26
Non-small Cell Lung Cancer Collaborative Group .
Chemotherapy in non-small cell lung cancer: meta-analysis using updated data on individual patients from 52 randomized clinical trials.
BMJ.
1995;
311
899-909
27
Rosell R, Gomez-Codina J, Camps C. et al .
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.
N Engl J Med.
1994;
330
153-158
28
Roth J A, Fossella F, Komaki R. et al .
A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.
J Natl Cancer Inst.
1994;
86
673-680
29
Eberhardt W, Wilke H, Stamatis G. et al .
Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results of a phase II trial.
J Clin Oncol.
1998;
16
622-634
30
Stamatis G, Eberhardt W, Stüben G. et al .
Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results.
Ann Thorac Surg.
1999;
68
1144-1149
31
Pisters K M, Ginsberg R J, Giroux D J. et al .
Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team.
J Thorac Cardiovasc Surg.
2000;
119
429-439
Dr. med. A. Marra
Abteilung für Thoraxchirurgie und thorakale Endoskopie, Ruhrlandklinik
Tüschener Weg 40
45239 Essen